|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0030705,
umls-concept:C0140080,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0280100,
umls-concept:C0541315,
umls-concept:C0920321,
umls-concept:C1261473,
umls-concept:C2713009
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-2-17
|
|
pubmed:abstractText |
Preclinical models demonstrate synergistic antitumor activity with combination blockade of mTOR and IGF-1R signaling. We aimed to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of figitumumab, a fully human IgG(2) anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (Pfizer) and the mTOR inhibitor, everolimus (Novartis). Pharmacokinetics and preliminary antitumor effects of the combination were evaluated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:ButrynskiJames EJE,
pubmed-author:DemetriGeorge DGD,
pubmed-author:GeorgeSuzanneS,
pubmed-author:HuftalenTarshaT,
pubmed-author:JederlinicNicoleN,
pubmed-author:ManolaJudithJ,
pubmed-author:MorganJeffrey AJA,
pubmed-author:QuekRichardR,
pubmed-author:RamaiyaNikhilN,
pubmed-author:ShapiroGeoffrey IGI,
pubmed-author:WagnerAndrew JAJ,
pubmed-author:WangQianQ
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
871-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21177764-Adult,
pubmed-meshheading:21177764-Aged,
pubmed-meshheading:21177764-Antibodies, Monoclonal,
pubmed-meshheading:21177764-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21177764-Female,
pubmed-meshheading:21177764-Humans,
pubmed-meshheading:21177764-Male,
pubmed-meshheading:21177764-Middle Aged,
pubmed-meshheading:21177764-Neoplasms,
pubmed-meshheading:21177764-Receptor, IGF Type 1,
pubmed-meshheading:21177764-Sarcoma,
pubmed-meshheading:21177764-Sirolimus,
pubmed-meshheading:21177764-TOR Serine-Threonine Kinases,
pubmed-meshheading:21177764-Treatment Outcome,
pubmed-meshheading:21177764-Tumor Burden,
pubmed-meshheading:21177764-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
|
|
pubmed:affiliation |
Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA,
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
